Robin Deterding, ERS 2022: Nintedanib for Children and Adolescents with Fibrosing Interstitial Lung Diseases
Nintedanib is an inhibitor of tyrosine kinases involved in the progression of pulmonary fibrosis and blocks the signalling pathways involved in fibrotic processes. We were delighted to speak to Dr. Robin Deterding (University of Colorado; Children’s Hospital Colorado, Aurora, CO, USA) around the incidence, prognosis and unmet needs in the treatment of childhood interstitial lung disease and the evidence supporting the investigation of nintedanib in this indication.
The abstract ‘Nintedanib in children and adolescents with fibrosing interstitial lung disease: the InPedILD trial.‘ was presented at ERS 2022, 4–6 September, 2022.
- Could you give us a brief overview of the incidence, prognosis and unmet needs in the treatment of childhood interstitial lung disease? (0:34)
- What evidence supports the investigation of nintedanib treatment for children and adolescents with fibrosing ILD? (3:32)
Disclosures: Robin Deterding discloses consulting for Boehringer Ingelheim; receiving grant/ research support from Boehringer Ingelheim; and serving on advisory boards for Boehringer Ingelheim.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
Share this Video
Related Videos In Paediatric Respiratory Medicine
Theresa W Guilbert, AAAAI 2023: The VOYAGE study: Impact of exacerbation history on dupilumab efficacy in children with asthma
Dupilumab is indicated as an add-on maintenance treatment in children aged 6 years and older with asthma, and demonstrated clinical efficacy in the pivotal VOYAGE study (NCT0294895). We caught up with Dr Theresa W Guilbert (Cincinnati Children’s Hospital & Medical Center; University of Cincinnati, Cincinnati, OH, USA) to discuss the main findings from a post-hoc […]
Theresa W Guilbert, AAAAI 2023: Health and economic burden of asthma exacerbations in children
touchRESPIRATORY were delighted to speak with Dr Theresa W Guilbert (Cincinnati Children’s Hospital & Medical Center; University of Cincinnati, Cincinnati, OH, USA) about the health and economic burden of asthma exacerbations in children, and the limitations of current therapeutic options for children with asthma. The abstract ‘Impact Of Exacerbation History On Dupilumab Efficacy In Children […]
Robin Deterding, ERS 2022: Findings from the InPedILD Trial
The InPedILD trial was a phase 3, double-blind placebo-controlled trial investigating nintedanib in children and adolescents with fibrosing interstitial lung diseases (ClinicalTrials.gov: NCT04093024). We were delighted to speak to Dr. Robin Deterding (University of Colorado; Children’s Hospital Colorado, Aurora, CO, USA) to discuss the aims, design, eligibility criteria and findings from the phase 3 study. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!